Anti-CD19 CAR T-Cells therapy (University Hospital Of Montpellier)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAnti-CD19 CAR T-Cells therapy (University Hospital Of Montpellier)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsScleroderma, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Of Montpellier

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Of Montpellier

Inactive CompaniesN/A

Active IndicationsScleroderma, Systemic

Inactive IndicationsN/A

Other Information

ATC CodeN/A